A detailed history of Tower Research Capital LLC (Trc) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 629 shares of BCYC stock, worth $9,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares
629
Previous 2,349 73.22%
Holding current value
$9,240
Previous $47,000 70.21%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.58 - $27.24 $33,677 - $46,852
-1,720 Reduced 73.22%
629 $14,000
Q2 2024

Aug 13, 2024

BUY
$20.02 - $24.69 $38,798 - $47,849
1,938 Added 471.53%
2,349 $47,000
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $32,109 - $50,033
-1,917 Reduced 82.35%
411 $10,000
Q4 2023

Feb 13, 2024

SELL
$13.29 - $22.2 $100,193 - $167,365
-7,539 Reduced 76.41%
2,328 $42,000
Q3 2023

Nov 14, 2023

BUY
$19.9 - $26.25 $148,195 - $195,483
7,447 Added 307.73%
9,867 $198,000
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $21,925 - $33,171
1,157 Added 91.61%
2,420 $61,000
Q1 2023

May 09, 2023

BUY
$20.02 - $31.37 $1,981 - $3,105
99 Added 8.51%
1,263 $27,000
Q4 2022

Feb 10, 2023

SELL
$20.37 - $32.9 $22,386 - $36,157
-1,099 Reduced 48.56%
1,164 $35,000
Q3 2022

Nov 10, 2022

BUY
$17.49 - $28.44 $20,708 - $33,672
1,184 Added 109.73%
2,263 $53,000
Q2 2022

Aug 15, 2022

BUY
$12.95 - $46.99 $8,844 - $32,094
683 Added 172.47%
1,079 $18,000
Q1 2022

May 12, 2022

SELL
$40.12 - $59.5 $133,639 - $198,194
-3,331 Reduced 89.37%
396 $17,000
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $155,415 - $227,868
3,727 New
3,727 $227,000
Q4 2019

Feb 07, 2020

SELL
$7.68 - $11.08 $706 - $1,019
-92 Closed
0 $0
Q3 2019

Nov 05, 2019

BUY
$6.74 - $12.01 $613 - $1,092
91 Added 9100.0%
92 $1,000
Q2 2019

Aug 13, 2019

BUY
$10.06 - $14.63 $10 - $14
1 New
1 $0

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $436M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.